Stock Ratings / Health Care / FATE / financials

LCTX (29) IPSC (28) OCGN (35) CABA (42) ⌘ Pro Terminal →

Fate Therapeutics Inc. (FATE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.17 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Fate Therapeutics Inc. (FATE) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $260.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FATE)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How FATE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $63.5M

FY24

Rev $13.6M

FY25

Rev $6.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$6.6M	52%	-80%	-$136.3M	-$112.0M	-45%
FY 2024	$13.6M	52%	-80%	-$186.3M	-$123.6M	-45%
FY 2023	$63.5M	52%	-80%	-$160.9M	-$132.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FATE)

✓Walkthrough of FATE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FATE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +73.60%▼ DESCENDING CHANNEL

2026-10-30O $2.13H $2.17L $2.01C $2.17VOL 1.06M

RES: $2.48SUP: $1.64SMA50: $2.29SMA200: $1.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FATE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FATE Butterfly Map → + Track FATE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -51.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FATE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FATE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FATE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FATE)

Health Care Rank #642 of 1016 ⚔️ LCTX vs FATE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FATE vs. LCTX, IPSC, OCGN, CABA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fate Therapeutics Inc. (FATE) ranks #642 by composite RQD confidence (40/100, grade D-) and #543 by equity capitalization ($260.0M). Within this direct 5-issuer industry benchmark cohort, FATE leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. CABA currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with FATE at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FATE ACTIVE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	Benchmark Subject
LCTX Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	/lctx-vs-fate →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-fate →
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-fate →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-fate →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001434316

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fate Therapeutics Inc. (FATE) reported GAAP revenue of $6.6M (-51.2% vs. FY2024 revenue of $13.6M , and -89.5% cumulative change since FY2023) , GAAP net income of -$136.3M, operating cash flow of -$106.1M, and free cash flow of -$112.0M (+9.4% YoY). On the balance sheet, FATE closed FY2025 with $318.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.6M	-$136.3M	-$106.1M	-$112.0M	$318.9M	—
FY2024 (FY)	2024-12-31	$13.6M	-$186.3M	-$122.9M	-$123.6M	$440.7M	—
FY2023 (FY)	2023-12-31	$63.5M	-$160.9M	-$132.3M	-$132.3M	—	—

3. FATE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FATE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Fate Therapeutics Inc. (NASDAQ: FATE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $2.17 (0.00% 1D, market cap $260.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FATE ranks #642 in composite RQD confidence.

How does FATE compare to LCTX and IPSC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FATE carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M) and IPSC (Century Therapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -14.1%, cap $264.4M). Among the 5-stock peer group, FATE leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FATE?

Per FATE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434316), Fate Therapeutics Inc. generated $6.6M in revenue (-51.2% YoY), -$136.3M in net income, and -$112.0M in free cash flow against $318.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FATE trading relative to its 50-day, 200-day, and 52-week technical levels?

FATE last traded at $2.17 (0.00% on volume of 804,294 shares), positioning the stock -5.24% below its 50-day simple moving average ($2.29) and +10.71% above its 200-day simple moving average ($1.96). Across its 52-week range of $0.95 to $3.23, FATE sits at the 53.5% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.90 to $2.44).